CORDIS
EU research results

CORDIS

English EN

Deacetylase inhibitors for autism spectrum disorders: an integrated preclinical validation pipeline in brain organoids and in vivo models

Project information

Grant agreement ID: 899727

Status

Ongoing project

  • Start date

    1 July 2020

  • End date

    31 December 2021

Funded under:

H2020-EU.1.1.

Hosted by:

UNIVERSITA DEGLI STUDI DI MILANO

Italy

Objective

ASD is a very prevalent neurodevelopmental condition affecting more than 1% individuals, and represents a major unmet medical need since no effective treatment is available. Despite the phenotypic convergence of its core symptoms (impaired language, restriction in sociability and stereotypies, invariably coupled to anxiety and often associated to varying degrees of intellectual disability), ASD is genetically highly heterogeneous, with hundreds of bona fide causative genetic lesions. This genetic architecture breaks down ASD into a collection of rare and highly penetrant genetic syndromes, presenting key challenges but also decisive applicative opportunities: i) the accelerated regulatory path for drug approval/repurposing; and ii) the possibility that few paradigmatic syndromes may yield generalizable therapeutic inroads for ASD treatment. Duplication at 7q11.23 (7Dup), encompassing 26-28 genes, is one of best characterized ASD-causing copy number variations and offers unique translational opportunities, also because hemydeletion of the same interval causes Williams-Beuren syndrome, a condition characterized by hypersociability and language strengths, thereby providing a unique reference standard to validate treatments for the core ASD symptoms. Within my ERC-Consolidator project we successfully completed a high-throughput screening on 7q11.23 CNV patient-derived neurons and discovered that deacetylase inhibition lowers the abnormal levels of a key gene underlying the cognitive/behavioral traits of 7Dup. Having defined robust 7Dup neurodevelopmental and electrophysiological phenotypes, both in patients’ neuronal lineages and in mouse models, we now aim to generate proof of concept for the preclinical validation of selected deacetylase inhibitors in rescuing ASD phenotypes in vitro and in vivo. For this we pursue an integrated experimental and business plan, buttressed by key industrial partnerships, to advance the most inhibitors towards ASD treatment.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

UNIVERSITA DEGLI STUDI DI MILANO

Address

Via Festa Del Perdono 7
20122 Milano

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 108 345

Beneficiaries (2)

UNIVERSITA DEGLI STUDI DI MILANO

Italy

EU Contribution

€ 108 345

ISTITUTO EUROPEO DI ONCOLOGIA SRL

Italy

EU Contribution

€ 41 655

Project information

Grant agreement ID: 899727

Status

Ongoing project

  • Start date

    1 July 2020

  • End date

    31 December 2021

Funded under:

H2020-EU.1.1.

Hosted by:

UNIVERSITA DEGLI STUDI DI MILANO

Italy